Lawrence A. Kenyon
2016
In 2016, Lawrence A. Kenyon earned a total compensation of $1.6M as Chief Financial Officer at Outlook Therapeutics, a 11,258% increase compared to previous year.
Compensation breakdown
| Salary | $309,359 |
|---|---|
| Stock Awards | $1,262,992 |
| Other | $17,727 |
| Total | $1,590,078 |
Kenyon received $1.3M in stock awards, accounting for 79% of the total pay in 2016.
Kenyon also received $309.4K in salary and $17.7K in other compensation.
Rankings
In 2016, Lawrence A. Kenyon's compensation ranked 5,969th out of 14,075 executives tracked by ExecPay. In other words, Kenyon earned more than 57.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,969 out of 14,075 | 58th |
Division Manufacturing | 2,167 out of 5,488 | 61st |
Major group Chemicals And Allied Products | 712 out of 1,900 | 63rd |
Industry group Drugs | 536 out of 1,543 | 65th |
Industry Biological Products, Except Diagnostic Substances | 101 out of 287 | 65th |
Source: SEC filing on September 29, 2017.
Kenyon's colleagues
We found three more compensation records of executives who worked with Lawrence A. Kenyon at Outlook Therapeutics in 2016.